One major goal of CoBi is the improvement of donor selection for unrelated haematopoietic stem cell transplantations. In order to move closer to this goal the DKMS has recently established the ‘DKMS COLLABORATIVE RESEARCH GRANT’. With this Grant, DKMS wants to promote joint studies to achieve improved donor selection criteria.
Research proposals can range from basic research, pre-clinical animal models to co-funded clinical trials. Those projects will be conducted as collaborative projects, and preference will be given to studies utilizing samples and/or data from DKMS (e.g. CoBi).
The Collaborative Research Grant will be awarded annually to provide a total funding for up to €1,000,000 over a maximum period of 3 years. The total funding amount may be awarded to a single applicant, or split into 2 separate awards. The program is funded by the DKMS Stiftung Leben Spenden and administered by DKMS gGmbH. Applicants must have a doctoral degree (M.D., Ph.D., or equivalent). Applicants do not necessarily need to hold a faculty position and can be in training (Fellows, Postdoctoral Fellows and Junior Faculty). The grant aims at interested scientists worldwide.
For more details and instructions regarding the general application process please click here and/or download the Summary Application Instructions and General Terms and Conditions. For general questions please get in contact with us by using our contact form.
Here you find an overview and summaries on research projects using the CoBi resources.
|Project Title||Impact of KIR2DS1 and KIR3DL1 donor gene content on outcome after allogeneic hematopoietic cell transplantation for patients with myeloid neoplasia|
|Principal Investigator||Prof. Dr. Johannes Schetelig|
|Summary||Improved donor selection based on immune-genetic markers may improve outcome after allogeneic hematopoietic cell transplantation (alloHCT). Until now, information on the degree of HLA-compatibility, donor age, donor sex and ABO blood group is considered for donor selection. A recent series of publications suggests that harnessing natural killer (NK) cell reactivity could further improve outcome after alloHCT. Especially, the presence of KIR2DS1 genes in the donor genome and advantageous combinations of KIR3DL1 donor content and HLA-Bw4 ligands in the patient have been associated with a reduced risk of relapse. This study aims at a validation of these recently reported findings.|